All In Biotech

Drug Trial Radar · NCT07058077

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Aug 21, 2025

Primary completion

Dec 4, 2033

Study completion Jan 23, 2037

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to learn if enlicitide decanoate is safe and effective to treat children and adolescents with heterozygous familial hypercholesterolemia (HeFH) and high amounts of low-density lipoprotein cholesterol (LDL-C) in the blood. The goals of this study are to learn about the safety of enlicitide and if children tolerate it, what happens to enlicitide in a child's body over time, and if enlicitide works to lower cholesterol levels in children more than a placebo.

Conditions

  • Heterozygous Familial Hypercholesterolemia (HeFH)

Interventions

  • Enlicitide DecanoateDrug

    Enlicitide decanoate taken by mouth

  • PlaceboDrug

    Placebo tablet matched to enlicitide decanoate taken by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Plasma Concentration (Cmax) of EnlicitideTime frame: At designated timepoints (up to 24 hours postdose on day 14)
  2. Part A: Area Under the Concentration-Time Curve from 0 to 24 Hours (AUC0-24) of EnlicitideTime frame: At designated timepoints (up to 24 hours postdose on day 14)
  3. Part B: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)Time frame: Baseline and Week 24
  4. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 188 weeks
  5. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 180 weeks

Locations

50 sites in 20 countries. Site status is shown where the registry gives one.

  • Nemours/Alfred I. duPont Hospital for Children ( Site 0001)

    Wilmington, Delaware · Recruiting

  • Children's National Medical Center ( Site 0015)

    Washington D.C., District of Columbia · Recruiting

  • Excel Medical Clinical Trials ( Site 0008)

    Boca Raton, Florida · Recruiting

  • Children's Healthcare of Atlanta Cardiology ( Site 0026)

    Atlanta, Georgia · Recruiting

  • Boston Children's Hospital ( Site 0018)

    Boston, Massachusetts · Recruiting

  • St. Louis Children's Hospital ( Site 0014)

    St Louis, Missouri · Recruiting

  • Cincinnati Children's Hospital Medical Center ( Site 0016)

    Cincinnati, Ohio · Recruiting

  • West Virginia University ( Site 0013)

    Morgantown, West Virginia · Recruiting

  • Monash Children s Hospital ( Site 1603)

    Clayton, Victoria, Australia · Recruiting

  • Perth Children s Hospital ( Site 1601)

    Nedlands, Western Australia, Australia · Recruiting

  • UZ Antwerpen ( Site 0601)

    Edegem, Antwerpen, Belgium · Recruiting

  • Instituto Dante Pazzanese de Cardiology ( Site 0206)

    São Paulo, Brazil · Recruiting

  • Incor - Instituto do Coracao ( Site 0200)

    São Paulo, Brazil · Recruiting

  • Universidade Federal Do Ceara ( Site 0201)

    Fortaleza, Ceará, Brazil · Recruiting

  • Hospital Dr. Hernan Henriquez Aravena ( Site 0301)

    Temuco, Araucania, Chile · Recruiting

  • Biocenter ( Site 0305)

    Concepción, Biobio, Chile · Recruiting

  • Explora Salud ( Site 0304)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile ( Site 0300)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Children's Hospital Capital Institute of Pediatrics ( Site 1908)

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Anzhen Hospital. Capital Medical University ( Site 1917)

    Beijing, Beijing Municipality, China · Recruiting

  • Guangdong Provincial People's Hospital ( Site 1915)

    Guangzhou, Guangdong, China · Recruiting

  • Children's Hospital of Fudan University ( Site 1906)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Children's Medical Center ( Site 1918)

    Shanghai, Shanghai Municipality, China · Recruiting

  • The Children's Hospital of Zhejiang University School of Medicine ( Site 1905)

    Hangzhou, Zhejiang, China · Recruiting

  • Clinica de la Costa S.A.S. ( Site 0400)

    Barranquilla, Atlántico, Colombia · Recruiting

  • Oncomédica S.A.S ( Site 0401)

    Montería, Departamento de Córdoba, Colombia · Recruiting

  • Fundación Cardiovascular de Colombia ( Site 0402)

    Piedecuesta, Santander Department, Colombia · Recruiting

  • Fundacion Valle del Lili ( Site 0403)

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Fakultni nemocnice v Motole ( Site 0700)

    Prague, Czechia · Recruiting

  • Detska nemocnice FN Brno ( Site 0701)

    Brno, Brno-mesto, Czechia · Recruiting

  • Vseobecna fakultni nemocnice v Praze ( Site 0702)

    Prague, Praha 2, Czechia · Recruiting

  • New Childrens Hospital ( Site 0800)

    Helsinki, Uusimaa, Finland · Recruiting

  • Hopital Femme Mere Enfant ( Site 2101)

    Bron, Rhone, France · Recruiting

  • Universitaetsklinikum Freiburg ( Site 2203)

    Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting

  • Chutoen General Medical Center ( Site 2003)

    Kakegawa, Shizuoka, Japan · Recruiting

  • INVECORDIS S.C. ( Site 0503)

    Huixquilucan, Mexico · Recruiting

  • Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" ( Site 0501)

    Monterrey, Nuevo León, Mexico · Recruiting

  • Centro de Investigacion Clinica de Oaxaca ( Site 0505)

    Oaxaca City, Oaxaca, Mexico · Recruiting

  • Amsterdam UMC, locatie AMC ( Site 1000)

    Amsterdam, North Holland, Netherlands · Recruiting

  • New Zealand Clinical Research (Christchurch) ( Site 1700)

    Christchurch, Canterbury, New Zealand · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.